J R Guyton

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Metabolic syndrome: evaluation of pathological and therapeutic outcomes
    Phillippa J Miranda
    Diabetes Division, University of Texas Health Science Center, San Antonio, Tex, USA
    Am Heart J 149:20-32. 2005
  2. ncbi request reprint Safety considerations with niacin therapy
    John R Guyton
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 99:22C-31C. 2007
  3. doi request reprint Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 51:1564-72. 2008
  4. ncbi request reprint An assessment by the Statin Intolerance Panel: 2014 update
    John R Guyton
    Division of Endocrinology, Diabetes, and Metabolism, Duke University Medical Center, 201 Trent Drive, Baker House 281, Durham, NC 27710, USA Electronic address
    J Clin Lipidol 8:S72-81. 2014
  5. pmc Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina Electronic address
    J Am Coll Cardiol 62:1580-4. 2013
  6. pmc Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study
    Ornit Chiba-Falek
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    BMC Med Genet 11:9. 2010
  7. doi request reprint Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 21:372-7. 2010
  8. ncbi request reprint Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 18:415-20. 2007
  9. ncbi request reprint Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group
    J R Guyton
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Arch Intern Med 160:1177-84. 2000
  10. ncbi request reprint Benefit versus risk in statin treatment
    John R Guyton
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 97:95C-97C. 2006

Detail Information

Publications30

  1. ncbi request reprint Metabolic syndrome: evaluation of pathological and therapeutic outcomes
    Phillippa J Miranda
    Diabetes Division, University of Texas Health Science Center, San Antonio, Tex, USA
    Am Heart J 149:20-32. 2005
  2. ncbi request reprint Safety considerations with niacin therapy
    John R Guyton
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 99:22C-31C. 2007
    ..Overall, the perception of niacin side effects is often greater than the reality. As a result, a valuable medication for cardiovascular risk is underused...
  3. doi request reprint Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 51:1564-72. 2008
    ..This study evaluated the safety and lipid-altering efficacy of ezetimibe/simvastatin (E/S) coadministered with extended-release niacin (N) in patients with type IIa or IIb hyperlipidemia...
  4. ncbi request reprint An assessment by the Statin Intolerance Panel: 2014 update
    John R Guyton
    Division of Endocrinology, Diabetes, and Metabolism, Duke University Medical Center, 201 Trent Drive, Baker House 281, Durham, NC 27710, USA Electronic address
    J Clin Lipidol 8:S72-81. 2014
    ..We identify a pressing need for further research on statin intolerance and make suggestions for research design. ..
  5. pmc Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina Electronic address
    J Am Coll Cardiol 62:1580-4. 2013
    ....
  6. pmc Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study
    Ornit Chiba-Falek
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    BMC Med Genet 11:9. 2010
    ..However, the mechanism underlying this gene by sex interaction has not been explored...
  7. doi request reprint Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 21:372-7. 2010
    ..To summarize recent studies on combination regimens that employ a statin with added niacin, ezetimibe, and/or bile acid sequestrants, and to understand the implications of these studies for clinical practice...
  8. ncbi request reprint Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 18:415-20. 2007
    ..This review describes niacin's mechanism of action, efficacy in cardiovascular prevention, and safety...
  9. ncbi request reprint Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group
    J R Guyton
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Arch Intern Med 160:1177-84. 2000
    ..To provide a direct comparison of agents that raise plasma levels of high-density lipoprotein cholesterol (HDL-C) to help devise strategies for coronary risk reduction...
  10. ncbi request reprint Benefit versus risk in statin treatment
    John R Guyton
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 97:95C-97C. 2006
    ..Statins should not be used in situations where minimal benefit is expected, as safety data and risk-benefit analysis must be meshed with guidelines that help the clinician decide whom to treat and how aggressively to treat...
  11. ncbi request reprint Extended-release niacin for modifying the lipoprotein profile
    John R Guyton
    Duke University Medical Center, Department of Medicine, Durham, North Carolina, USA
    Expert Opin Pharmacother 5:1385-98. 2004
    ..Thus, niacin ER represents an effective and safe option in the management of low levels of HDL-C and other lipoprotein abnormalities in a variety of settings...
  12. doi request reprint Metabolic syndrome
    Lillian F Lien
    Department of Medicine, Division of Endocrinology, Sarah W Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Dermatol Ther 21:362-75. 2008
    ..Treatments can include not only pharmacologic approaches but behavior modification as well...
  13. ncbi request reprint Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses
    Eric C Westman
    Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Int J Cardiol 110:212-6. 2006
    ..Low-carbohydrate, ketogenic diets (LCKD) are effective for weight loss, but concerns remain regarding cardiovascular risk. The purpose of this study was to determine the effect of an LCKD program on serum lipoprotein subclasses...
  14. ncbi request reprint Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy
    W Lane Duvall
    Department of Medicine, Box 3510, Duke University Medical Center, Durham, NC 27710, USA
    J Cardiovasc Risk 9:339-47. 2002
    ..This dual strategy will require a well tolerated, effective regimen, as well as a better understanding of how HDL-C may be targeted...
  15. ncbi request reprint Implanted estrogen pellets associated with hypertriglyceridemia, biliary dyskinesia and focal nodular hyperplasia of the liver: a case report
    Eric J Forman
    Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3616, Durham, NC 27710, USA
    J Reprod Med 55:87-90. 2010
    ..Bioidentical hormones, including implanted estradiol-17beta pellets, have received considerable interest in the lay media. It is thought that parenteral estrogens have fewer gastrointestinal side effects than oral products...
  16. ncbi request reprint A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial
    William S Yancy
    Center for Health Services Research in Primary Care, Department of Veterans Affairs Medical Center, and Duke University Medical Center, Durham, North Carolina 27705, USA
    Ann Intern Med 140:769-77. 2004
    ..Low-carbohydrate diets remain popular despite a paucity of scientific evidence on their effectiveness...
  17. ncbi request reprint Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia
    Nicole E Jelesoff
    Department of Medicine, Division of Endocrinology, Nutrition, and Metabolism, Duke University Medical Center, Durham, North Carolina 27710, USA
    Endocr Pract 12:159-64. 2006
    ..To determine the effectiveness and tolerability of adding ezetimibe, 10 mg daily, to niacin-based regimens for dyslipidemia...
  18. ncbi request reprint Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury
    Haichen Wang
    Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
    Exp Neurol 206:59-69. 2007
    ..Furthermore, statin treatment improved cerebral hemodynamics following head injury. Thus, the administration of statins may represent a viable therapeutic strategy in the acute treatment of closed head injury...
  19. pmc Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study
    Sunil Suchindran
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Genet 6:e1000928. 2010
    ..3 near the PLA2G7 gene. Our analyses demonstrate that genetic polymorphisms may contribute to inter-individual variation in Lp-PLA(2) activity and mass...
  20. ncbi request reprint Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia
    Antonios M Xydakis
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 6565 Fannin Street, Houston, TX 77030, USA
    Am J Cardiol 94:795-7. 2004
    ..03), without significantly changing high-density lipoprotein cholesterol, and the combination was well tolerated...
  21. ncbi request reprint Safety considerations with gastrointestinally active lipid-lowering drugs
    Terry A Jacobson
    Emory University, Office of Health Promotion and Disease Prevention, Atlanta, Georgia 30303, USA
    Am J Cardiol 99:47C-55C. 2007
    ..Overall, CAIs and BAS have excellent systemic safety profiles when used alone or in combination with other lipid-lowering drugs...
  22. ncbi request reprint Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia
    Moti L Kashyap
    Veterans Affairs Healthcare System, Long Beach, California 90822, USA
    Am J Cardiol 89:672-8. 2002
    ..5%. Once-daily niacin/lovastatin exhibits substantial effects on multiple lipid risk factors and represents a significant new treatment option in the management of dyslipidemia...
  23. ncbi request reprint Statin safety: an assessment using an administrative claims database
    Mark J Cziraky
    HealthCore, Inc, Wilmington, Delaware 19801, USA
    Am J Cardiol 97:61C-68C. 2006
    ..No hospitalized cases of the index AEs were observed in study subjects during the 6-month period before initiation of the lipid-lowering drug. Statin monotherapy as currently prescribed is generally well tolerated and safe...
  24. doi request reprint The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk
    Vincent E Friedewald
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Am J Cardiol 102:559-67. 2008
  25. ncbi request reprint Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study
    Ronald B Goldberg
    Diabetes Research Institute, Miller School of Medicine, University of Miami, 1450 NW 10th Ave, Miami, FL 33136, USA
    Mayo Clin Proc 81:1579-88. 2006
    ..To compare the efficacy and safety of the recommended usual starting and next highest doses of ezetimibe/ simvastatin and atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia...
  26. ncbi request reprint Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
    David D Waters
    University of California, San Francisco School of Medicine, San Francisco, California 94110, USA
    Am J Cardiol 93:154-8. 2004
    ..9 mmol/L) can provide additional clinical benefit...
  27. ncbi request reprint Metabolic syndrome: definition, pathophysiology, and mechanisms
    Phillippa J Miranda
    Diabetes Division, University of Texas Health Science Center, San Antonio, Tex, USA
    Am Heart J 149:33-45. 2005
  28. ncbi request reprint Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Counc
    Larry B Goldstein
    Stroke 37:1583-633. 2006
    ..This guideline provides an overview of the evidence on various established and potential stroke risk factors and provides recommendations for the reduction of stroke risk...
  29. ncbi request reprint Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
    James M McKenney
    National Clinical Research, Virginia Commonwealth University, Richmond, Virginia 23294, USA
    Am J Cardiol 97:89C-94C. 2006
    ..Practical guidance in the form of recommendations to health professionals who manage the coronary artery disease risk of patients with statin therapy is provided...
  30. ncbi request reprint Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Counc
    Larry B Goldstein
    Circulation 113:e873-923. 2006
    ..This guideline provides an overview of the evidence on various established and potential stroke risk factors and provides recommendations for the reduction of stroke risk...